New CAR-T therapy targets tough T-Cell cancers in early trial
NCT ID NCT06874946
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of CAR-T cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: first, finding the safest dose, then testing how well it works in 30 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD5-targeted CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat T-cell cancers that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug spare healthy cells while killing lymphoma?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted pill boost Chemo's power against a rare blood cancer?
- Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma
- New study aims to decode PTCL by genetic subtype
- New hope for tough lymphoma: TR115 faces off against standard care